Image source: Public Domain
Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, announced that its FDA-cleared platform, Unfold AI, is now in use across the entire prostate cancer care continuum, including active surveillance, focal therapy, surgery, and radiotherapy. Unfold AI combines MRI, pathology, biomarkers, and clinical data to create personalized 3D prostate cancer maps that physicians use to plan and guide treatment.
Unfold AI Use Cases:
Unfold AI can be used to guide treatment planning across multiple options rather than pointing toward a single intervention, helping physicians and patients weigh choices with more complete information. It has even been shown to shift physicians' treatment recommendations toward more minimally invasive options in one in three cases.
"Every treatment decision in prostate cancer starts with understanding where the cancer is and how far it extends," said Shyam Natarajan, PhD, co-founder and CEO of Avenda Health. "Our goal is to arm physicians with data to make better-informed recommendations that are personal to the patient's specific disease. Our platform's growing clinical adoption reflects the need for more accurate information at every treatment stage."
Today, Unfold AI is in use at major academic centers, including the University of California, Los Angeles, the University of Alabama at Birmingham, and the University of Michigan Health, alongside community-based practices in Arizona, Maryland, Florida, New York, and California.
By subscribing, you agree to receive email related to content and products. You unsubscribe at any time.
Copyright 2026, AI Reporter America All rights reserved.